Ignite Creation Date:
2024-06-16 @ 11:48 AM
Last Modification Date:
2024-10-26 @ 3:30 PM
Study NCT ID:
NCT06427330
Status:
RECRUITING
Last Update Posted:
2024-05-23
First Post:
2024-05-10
Brief Title:
Phase II Study of Post-Transplant Low-Dose Inotuzumab Ozogamicin to Prevent Relapse of Acute Lymphoblastic Leukemia
Sponsor:
Institute of Hematology Blood Diseases Hospital China
Organization:
Institute of Hematology Blood Diseases Hospital China
Organization Data
Organization:
Institute of Hematology Blood Diseases Hospital China
Class:
OTHER
Study ID:
IIT2024022-EC-1
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Institute of Hematology Blood Diseases Hospital China
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None